A Study Evaluating the Value of 68Ga-Pentixafor PET Imaging in the Staging of Hematological Tumor, and Comparing It with 18F-FDG PET/CT Imaging

Launched by XIJING HOSPITAL · Feb 13, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new type of imaging called 68Ga-Pentixafor PET to see if it can help doctors better understand and treat certain blood cancers, specifically non-Hodgkin's lymphoma and myeloma. The study involves 120 patients who will undergo two different imaging tests: the standard 18F-FDG PET/CT scan and the new 68Ga-Pentixafor PET/CT scan. Researchers want to find out if the new imaging method provides additional valuable information for staging the cancer, checking how well treatment is working, and re-evaluating the cancer later on.

To be eligible for this trial, participants should be between 18 and 75 years old, have a confirmed diagnosis of non-Hodgkin's lymphoma or myeloma, and be able to follow the study guidelines. Importantly, they should not have severe liver or kidney issues, nor can they be pregnant or breastfeeding. If someone joins the study, they can expect to have both imaging tests done and contribute to important research that could improve cancer care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ages 18 to 75 years old Confirmed by pathology with NHLs or myeloma Willing and able to follow the study protocol.
• Exclusion Criteria:
• • Children, pregnant or lactating women Severely impaired liver and kidney function (alanine aminotransferase \> 8-10 times the upper limit of normal, serum creatinine 186-442 umol/L) With a history of allergy to contrast media or other drugs